Welsbach Technology Metals Acquisition Corp. announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “WTMAU” Tuesday, December 28.
The new SPAC intends to concentrate its search efforts on targets in the technology metals and energy transition materials industry. Welsbach Technology Metals is led by CEO and Chairman Daniel Mamadou, COO Christopher Clower, CFO John Stanfield, and VP Sergey Marchenko.
Total SPAC deal count for 2021 year-to-date is now 612. This offering is expected to close on Thursday, December 30.
Chardan is acting as sole book-running manager of the offering. Ellenoff Grossman & Schole LLP is serving as Issuer’s Counsel with Hunter Taubman Fischer & LI LLC serving as Underwriter’s Counsel. UHY LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...